The Globe and Mail reports in its Tuesday, Sept. 30, edition that RBC Dominion Securities analyst Douglas Miehm rates Concordia Healthcare ($36.18) "outperform" in new coverage. The Globe's Darcy Keith and Jody White write in the Eye On Equities column that Mr. Miehm targets the shares at $46. Mr. Miehm says Concordia "has reached a level of maturity that should allow it to accelerate its growth profile and generate outsized returns over the next several years." Concordia aims to acquire assets with durable cash flows that have additional growth capacity plus a strong safety record. Mr. Miehm says: "We believe the strategic risk is lower than that of traditional pharma companies and its commercialization strategy requires limited capital to alter the cash flow trajectory of products. ... While Concordia has been very successful in growing its business and capitalization since early 2014, we believe that it has now entered the 'sweet spot' in a specialty pharma company's normal growth curve. This is a point where the cost of capital is at attractive levels and small acquisitions can still lead to outsized accretion and value creation." The analyst consensus price target over the next year is $44.38.